5月21日,罗氏宣布美国FDA授予其在研口服疗法inavolisib突破性疗法认定,通过与palbociclib(哌柏西利)和fulvestrant(氟维司群)联合使用,用于治疗PIK3CA突变、激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)、在完成辅助内分泌治疗后或12...
2024年4月2日,国家药监局药品审评中心(CDE)官网显示,罗氏PI3K抑制剂GDC-0077(通用名:Inavolisib)纳入突破性治疗品种名单,与哌柏西利和内分泌疗法联合用于治疗PIK3CA突变、激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性、局部晚期...
GDC-0077是一种有效的、口服的选择性PI3Kα抑制剂，其兼具高选择性抑制PI3Κα并且能特异性降解PI3Κα突变蛋白的双重作用机制，可以实现持续的通路抑制。通用名：Inavolisib 代号：GDC-0077 靶点：PI3K 厂家：罗氏（Roche）美国首次获批：尚未获批 中国首次获批：尚未获批 临床数据 此次的新药申请（NDA）是得到了来自...
2009;8:627–644. 9.Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30:194–204. 10.Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006; 18:77–82....
2005;30:194–204. 10.Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006; 18:77–82. 11.Yang QS, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: First-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic...
CVL237片作为在多类疾病中均具有极大治疗潜力的创新药物,有望成为下一款BestinClass新药。 肿瘤领域布局丰富 多款药物临床加速 甫康药业在肿瘤领域已拥有丰富管线,覆盖实体瘤、血液瘤等多类癌症,包括2.4类新药马来酸奈拉提尼片、第二代PARP抑制剂CVL218以及联合疗法等。
Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer, 2017, 141(2): 287-297. 9. Raza W, Luqman S, Meena A. Prospects of tangeretin as a modulator of cancer targets/pathways. Pharmacol Res, 2020, ...
GDC-0077是一种有效的、口服的选择性PI3Kα抑制剂。 2024年5月29日,罗氏(Roche)宣布,其在研的选择性PI3Kα抑制剂GDC-0077(通用名:Inavolisib)的新药申请(NDA)已获得美国食品药品监督管理局(FDA)受理,并授予了优先审查。此次的适应症为:联合CDK4/6抑制剂哌柏西利和氟维司群用于治疗携带PIK3CA突变、激素...
(IR) HepG2 cells. All flavonoids improves theglucose consumptionandglycogen synthesisabilities in IR-HepG2 cells via activating glucose transporter protein 4 (GLUT4) and phosphor-glycogen synthase kinase (GSK-3β). These flavonoids significantly inhibited the production ofreactive oxygen species(ROS)...
中华普通外科杂 志,2015,30(2):135-139. [15] Chi H. Regulation and function of mTOR signalling in T cell fate decisions[J]. Nat Rev Immunol,2012,12(5):325-338. [16] Shi LZ,Wang R,Huang G,et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the ...